STOCK TITAN

ASTELLAS PHARMA UNSP/ADR - $ALPMY STOCK NEWS

Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: $ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ASTELLAS PHARMA UNSP/ADR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ASTELLAS PHARMA UNSP/ADR's position in the market.

Rhea-AI Summary
Astellas Pharma announced that the China National Medical Products Administration has accepted the Biologics License Application for zolbetuximab, a targeted monoclonal antibody for gastric cancer treatment in China. China accounts for nearly half of the world's new cases of gastric cancer. The BLA is based on Phase 3 clinical trials, and if approved, zolbetuximab would be the first therapy of its kind available in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
-
Rhea-AI Summary
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted its marketing authorization application for zolbetuximab, a first-in-class investigational monoclonal antibody for the treatment of gastric cancer. If approved, zolbetuximab would be the first therapy of its kind available in Europe. Gastric cancer accounted for 3.1% of all new cancer cases in Europe in 2020, with an average five-year survival rate of 26% across all stages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
Rhea-AI Summary
Astellas Pharma Inc. has completed the acquisition of IVERIC bio, Inc. Iveric Bio is now Astellas' wholly-owned subsidiary. The acquisition was completed on July 11, 2023, following all necessary approvals. Astellas aims to become a leader in the development and commercialization of treatments for retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
ASTELLAS PHARMA UNSP/ADR

OTC:ALPMY

ALPMY Rankings

ALPMY Stock Data

16.87B
1.79B
0%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Chuo Ku